Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat parkinsonism. by Yung, KK et al.
Title Endogenous repair by the activation of cell survival signallingcascades during the early stages of rat parkinsonism.
Author(s) Lui, NP; Chen, LW; Yung, WH; Chan, YS; Yung, KK
Citation PLoS One, 2012, v. 7, p. e51294
Issued Date 2012
URL http://hdl.handle.net/10722/184664
Rights Creative Commons: Attribution 3.0 Hong Kong License
Endogenous Repair by the Activation of Cell Survival
Signalling Cascades during the Early Stages of Rat
Parkinsonism
Nga-Ping Lui1, Liang-Wei Chen2, Wing-Ho Yung3, Ying-Shing Chan4, Ken Kin-Lam Yung1*
1Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, 2 Institute of Neurosciences, The Forth Military Medical University, Xian, PR China,
3 School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, 4Department of Physiology and Research Centre of Heart,
Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong
Abstract
Here we report a previously unknown self repair mechanism during extremely early stages of rat Parkinsonism. Two
important cell survival signaling cascades, Phosphatidylinositol-3 kinases (PI3K)/Akt pathway and extracellular signal-
regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway, could be responsible for this potential
endogenous rescue system. In the 6-hydroxydopamine-lesioned rat, the phosphorylated p44/42 MAPK and its downstream
target, the phosphorylated Bad at Ser 112, were up-regulated at post-lesion day 3 and lasted for a couple of weeks.
Although the change in the phosphorylated Akt kinase was negligible throughout the studied period, its downstream
target, the phosphorylated Bad at 136, was increased from post-lesion day 3 to post-lesion day 14. In the mean time, nestin-
positive reactive astrocytes with low levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived
neurotrophic factor (GDNF) appeared at post-lesion day 3 in 6-hydroxydopamine-lesioned rat. BDNF was expressed in both
striatum and substantia nigra whereas GDNF was displayed in striatum only. At post-lesion day 14, nestin, BDNF and GDNF
expressions were diminished. These neurotrophic factors were believed to initiate the above anti-apoptotic signal
transduction cascades as we could see that their expression patterns were similar. The data strongly suggest that there is an
endogenous repair effort by evoking the cell survival signaling and possibly via the releases of BDNF and GDNF from nestin-
immunoreactive reactive astrocytes. ERK/MAPK pathway was proposed to be the key endogenous neuroprotective
mechanisms, particularly in early stages of rat Parkinsonism. However, the self repair effort is only functional within an
extremely short time window immediately after onset.
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Introduction
Parkinson’s disease is a serious movement disorder and the sine
qua non of Parkinson’s disease is the massive loss of dopaminergic
neurones in the substantia nigra pars compacta [1], [2], [3], [4],
[5]. Neuroprotection and restoration of the dopaminergic
neurones are the therapeutics strategies against Parkinson’s disease
in humans. It was reported that apoptosis caused the neuronal
degeneration of PD [6], [7]. Moreover, a pro-apoptotic environ-
ment could be detected in the nigrostriatal region of Parkinsonism
[7]. The apoptotic death of cells was characterized by the
expression of oncogenes, including the apoptotic promoter (Bcl-
XS, Bax and Bad) as well as the apoptotic inhibitors (Bcl-2, Bcl-XL)
[6], [8]. The balance of the death and the survival signals
determined the fate of the cell.
Bad (Bcl-XL/Bcl-2 associated death promoter) is a pro-
apoptotic member of Bcl-2 family. It can provoke an apoptotic
cascade by forming a heterodimer with either Bcl-2 or Bcl-XL.
The antagonistic effect of Bad on the survival-promoting activity is
stronger than the other apoptotic promoters [9]. The phosphor-
ylation of Bad results in releasing Bcl-2 and Bcl-XL and thus
inhibiting the apoptotic program. The increase in several
phosphorylated kinase, such as Akt and MAPK, also accompany
the phosphorylated Bad and enhance cell survival [9], [10], [11].
Akt kinase exerts a direct effect on the cell survival pathway by
targeting the pro-apoptotic Bad and mediating the phosphoryla-
tion of Bad at Ser 136. Besides the release of Bcl-2 and Bcl-XL,
Bad creates a binding site to 14-3-3 proteins and allows the
inactivation of its apoptotic property [12]. Like Akt pathway,
MAPK pathway is considered as a crucial cell survival pathway
against the apoptosis. The activation of the p44/42 MAPK
(ERK1/2) pathway requires the phosphorylation of threonine and
tyrosine residues [13]. ERK1 and ERK2 are homologous isoforms
and share similar substrate specificities [14]. The activation of the
MAPK kinase can suppress the activity of Bad by inducing the
phosphorylation of Bad at Ser 112 [15]. It is suggested that Akt
and MAPK signaling pathways converge at Bad and inhibit cell
death.
In the present study, the changes in Akt and MAPK signaling
pathways during early stages of Parkinson’s disease would be
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explored by using the 6-hydroxydopamine (6-OHDA)-lesioned rat
model. We suggested that the re-appearance of nestin-postive
reactive astrocytes with the up-regulations of brain-derived
neurotrophic factor (BDNF) and glial cell line-derived neuro-
trophic factor (GDNF) could potentially induce this self repair
mechanism.
Materials and Methods
Animals
All experiments were conducted with female Sprague-Dawley
(SD) rats weighting from 200 to 220 g. The animal experimental
protocols performed in this study strictly confirmed to the guidelines
of the Animals (Control of Experiments) Ordinance, Department of
Health, Hong Kong, and approved by the Committee on the Use of
Human and Animal Subjects in Teaching and Research, Hong
Kong Baptist University, and also conformed to the Principles of
Laboratory Animal Care (NIH publication no. 86-23, revised
1985). All procedures performed were aimed to minimize both
animal number and suffering of the animals.
6-hydroxydopamine lesion
The striatal 6-OHDA lesion was performed in this experiment
[16], [17], [18], [19], [20], [21], [22]. [23]. The SD rats were
divided into following groups, i.e. post-lesion day 1 (n = 5), day 3
(n = 5), day 5 (n = 5), day 7 (n= 5), day 14 (n= 5) and control
(n = 25). The SD rats were first anesthetized with 2–3 m1 of
sodium pentobarbital (60 mg/kg; i.p.; Saggittal) before the surgery
of lesion. 6 ul of a 6-OHDA solution (Sigma; 3 mg/ml) dissolved
in ascorbic acid solution (0.2 mg/ml in 0.9% saline) was then
stereotaxically injected at point one: Bregma: +0.l4 cm, Medline:
20.26 cm, Dura: 20.5 cm, and point two: Bregma: 20.04 cm,
Medline: 20.38 cm, Dura: 20.5 cm in accordance to the atlas of
Paxinos and Watson, (1986). Control group was done by
administrating 6 ul of 0.9% saline instead of 6-OHDA solution.
At above survival dates after 6-OHDA lesion, the rats were
administrated with apomorphine (1 mg/ml; i.p.; RBI) for the test
of the rotational behaviour [24], [25].
Western blotting
The animals were sacrificed by decapitation. The brains were
immediately removed. The whole striatum and substantia nigra
were rapidly dissected and placed on the ice. The target proteins
were extracted from each samples protein of the brain. Samples
were homogenized with the suggested buffer and then centrifuged at
13,0006g for 30 min at 4uC. The resultant supernatants were
collected and frozen at 280uC until analysis. 50 mg of protein
sample was used. The sample proteins were resolved in SDS-PAGE
gels by electrophoresis and were blotted to nitrocellulose mem-
branes through standardWestern blotting protocol [26]. Blocking of
nonspecific binding was done by incubating the membranes with
5% non-fat milk for 2 hours at room temperature and then with the
primary antibodies in 2% non-fat milk overnight at 4uC. The
antibodies used were chicken anti-GDNF (Millipore), sheep anti-
BDNF (Millipore), rabbit anti-phosphorylated Akt (Ser 473; Cell
Signaling Technology), rabbit anti-Akt (pan; Cell Signaling
Technology), mouse anti- phosphorylated p44/42 MAPK (Erk1/
2) (Thr202/Tyr204; Cell Signaling Technology), rabbit anti- p44/
42 MAPK (Erk1/2; Cell Signaling Technology), rabbit anti-Bad
(Ser 136; Cell Signaling Technology) and rabbit anti-Bad (Ser 112;
Cell Signaling Technology) in the ratio of 1 to 1000, and rabbit anti-
TH (Millipore) and mouse anti-b actin (Millipore) in the ratio of 1 to
3000. After rinsing the membranes with TBS-T and TBS several
times, they were incubated with the appropriate horseradish
peroxidase [HRP]-conjugated secondary antibodies (1:4000;
Zymed Laboratories Inc.) against the primary antibodies for 1 hour
at room temperature. Bands on the membranes were visualized
using chemiluminescence detection (ECL Western blotting detec-
tion reagents; Amersham Pharmacia). Images of the bands were
developed on films (Biomax X-ray film; Kodak).
BDNF and GDNF ELISA assays
BDNF and GDNF proteins were measured by BDNF Emax
immunoassay system and GDNF Emax immunoassay system
(Promega, Madison, WI) according to the protocols of the
manufacturer respectively. 50 mg of protein sample was used.
The wells of 96-well plate were coated well with the respective
monoclonal antibodies and incubated overnight at 4uC. After
several washes with TBS-T, Block & Sample 16buffer was added
for the non-specific binding blocking for 1 hour at room
temperature, following with the incubation of extracted samples
and the standards with the immobilized monoclonal antibodies for
2 hours at room temperature. The incubations of the appropriate
polyclonal antibodies and the Anti-IgY HRP conjugates were then
done. 3,39,5,59-tetramethylbenzidine (TMB) one solution was
added for the colour development which was detected by a
multi-functional plate reader (Tecan Infinit F200) at 450 nm.
Immunofluorescence
Immunofluorescence was performed to illustrate the immunore-
activity for nestin (MAB353; Chemicon/Millipore) and tyrosine
hydroxylase (TH; MAB318; Chemicon/Millipore). The striatum
and substantia nigra sections were incubated overnight with rabbit
anti-nestin (1:500) and mouse anti-TH (1:2000) in PBS (0.01 M,
pH 7.4) with 0.1% Triton-X (Fluka) and 2% normal goat serum
(Vector Laboratories Inc.) at room temperature. The sections were
then rinsed with PBS and incubated in Alexa 488-conjugated
secondary antibody solution which was anti-primary origins IgG
(1:500; Molecular Probes) for 2 hours in dark at room temperature.
After being rinsed with PBS, the sections were mounted on clean
slides with fluorescent mounting medium (Dako) and covered with
coverslips for the examination under the same parameters with laser
scan confocal microscope (Olympus fluoview 1000).
Double immunofluorescence
For characterization of nestin immunoreactive cells, double
immunofluorescence was performed in the striatum and substantia
nigra sections of the 6-OHDA-treated rats in order to visualize
cellular co-localization of nestin with glial fibrillary acidic protein
(GFAP; Millipore), GDNF (Millipore) and BDNF (Millipore). The
procedures were similar to that of the simple immunofluorescence.
The striatum and substantia nigra sections were incubated
overnight at room temperature with a mixture of two different
antibodies. For nestin/GFAP double labeling and nestin/GDNF
double labeling, rabbit anti-nestin (1:500) with rat anti-GFAP
(1:1000) and rabbit anti-nestin (1:500) with chicken anti-GDNF
(1:100), were diluted in PBS (0.01 M; pH 7.4) with 0.1% Triton-X
and 2% normal goat serum. For nestin/BDNF double labeling,
rabbit anti-nestin (1:500) with sheep anti-BDNF (1:500) were
diluted in PBS (0.01 M; pH 7.4) with 0.1% Triton-X, 2% NGS
and 2% normal donkey serum (Equitech-Bio). After incubation,
the sections were rinsed with PBS and incubated with a mixture of
FITC-conjugated anti-rabbit IgG (1:500) and Cy5-conjugated
anti-rat IgG (1:500; Molecular Probes) for nestin/GFAP double
labeling, a mixture of FITC-conjugated anti-rabbit IgG (1:500)
and Rhodamine- conjugated anti-chicken IgG (1:500; Molecular
Probes) for nestin/GDNF double labeling, and a mixture of FITC-
conjugated anti-rabbit IgG (1:500) and Rhodamine-conjugated
Self-Repair System in Parkinson’s Disease
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anti-sheep (1:500; Molecular Probes) for nestin/BDNF double
labeling for 2 hours in dark at room temperature. After being
rinsed with PBS, the sections were mounted on clean slides with
fluorescent mounting medium and covered with coverslips for the
examination under the same parameters with laser scan confocal
microscope.
Semi-quantitative analysis
For all the immunofluorescence, the immunoreactivities for
nestin, GDNF, BDNF and TH in terms of average grey value by
the immunofluorescence staining method were analyzed by
software (Metamorph; Universal Imaging). The values were
analyzed by statistic program, namely SPSS. And one-way
ANOVA (SPSS) was employed to calculate the significant
Figure 1. Images showing the TH immunoreactivity of striatum and substantia nigra in 6-hydroxydopamine-lesioned animals
amongst different time points under Western blotting. (A) Control; (B) at post-lesion day 1; (C) at post-lesion day 3; (D) at post-lesion day 5; (E)
at post-lesion day 7; (F) at post-lesion day 14. The graphs illustrating the time-dependant patterns of tyrosine hydroxylase reactivity in striatum (G)
and substantia nigra (H) during post-lesion period. The change in the apomorphine- induced rotation numbers during post-lesion period (I).
**p,0.01; ***p,0.001, compared to control group and 6- OHDA- lesioned group (post- lesion day 1).
doi:10.1371/journal.pone.0051294.g001
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difference between different groups. At least fifteen views from five
rats for each group (both sides of striatum and substantia nigra
groups) were used for the analysis. For the double labeling, the
images of nestin/GFAP, nestin/GDNF and nestin/BDNF double-
labeled cells were captured per animal with 3 represented sections
[n= 5]. The total cell numbers were counted and presented in mean
Figure 2. Western Blotting analysis showing that the expression of phosphorylated p44/42 MAPK in both striatum and substantia
nigra of the 6- hydroxydopamine-lesioned rats as well as control group amongst different time points. (A) Control; (B) at post-lesion
day 1; (C) at post-lesion day 3; (D) at post-lesion day 5; (E) at post-lesion day 7; (F) at post-lesion day 14. The expression patterns of phosphorylated
p44/42 MAPK which normalized with p44/42 MAPK in striatum and substantia nigra amongst different post-lesion time points. (G) Striatum; (H)
substantia nigra. **p,0.01; ***p,0.001, compared to control group and ipsilateral side of treated group (post- lesion day 1). ##p,0.01, compared to
control group and contralateral side of treated group (post- lesion day 1). a p,0.05; aa p,0.01; aaa p,0.001, compared to contralateral side of treated
group with the respective time point.
doi:10.1371/journal.pone.0051294.g002
Self-Repair System in Parkinson’s Disease
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6 S.E.M.. The nomenclature and description of brain structure
were utilized in reference of the atlas of Paxinos and Watson (1986).
Controls for the single and double immunofluorescence trials were
performed by omission of either the primary or secondary
antibodies in the original reaction sequences.
Figure 3. Western Blotting analysis showing that the expression of phosphorylated Bad at Ser 112 in both striatum and substantia
nigra of the 6- hydroxydopamine-lesioned rats as well as control group amongst different time points. (A) Control; (B) at post-lesion
day 1; (C) at post-lesion day 3; (D) at post-lesion day 5; (E) at post-lesion day 7; (F) at post-lesion day 14. The expression patterns of phosphorylated
Bad at Ser 112 which normalized with b-actin in striatum and substantia nigra amongst different post-lesion time points. (G) Striatum; (H) substantia
nigra. **p,0.01; ***p,0.001, compared to control group and ipsilateral side of treated group (post- lesion day 1). #p,0.05; ##p,0.01, compared to
control group and contralateral side of treated group (post- lesion day 1). a p,0.05; aa p,0.01; aaa p,0.001, compared to contralateral side of treated
group with the respective time point.
doi:10.1371/journal.pone.0051294.g003
Self-Repair System in Parkinson’s Disease
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In the Western blotting, optical density of each band was then
semi-quantified by Metamorph as well. Control for loading was
done in revealing beta-actin proteins using either striatal or nigral
tissues of the same animals. Specific bands of 45 kDa were
revealed in each of the trial. The optical densities of the bands of
BDNF and GDNF were normalized using the optical densities of
the bands of beta-actin. The ratios were obtained and statistically
analyzed by one-way ANOVA. For ELISA assays, BDNF and
GDNF levels were calculated from the standard curve prepared
for each plate with SPSS. Data are presented as mean6S.E.M.
and compared using one-way ANOVA.
Figure 4. Western Blotting analysi showing the expression of phosphorylated Akt in both striatum and substantia nigra of the 6-
hydroxydopamine lesioned rats as well as control group amongst different time points. (A) Control; (B) a post-lesion day 1; (C) a post-
lesion day 3; (D) at post-lesion day 5; (E) at post-lesion day 7; (F) at post-lesion day 14. The expression patterns of phosphorylated Akt which
normalized with Akt in striatum and substantia nigra amongst different post-lesion time points. (G) Striatum; (H) substantia nigra.
doi:10.1371/journal.pone.0051294.g004
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Figure 5. Western Blotting analysis showing that the expression of phosphorylated Bad at Ser 136 in both striatum and substantia
nigra of the 6- hydroxydopamine-lesioned rats as well as control group amongst different time points. (A) Control; (B) at post-lesion
day 1; (C) at post-lesion day 3; (D) at post-lesion day 5; (E) at post-lesion day 7; (F) at post-lesion day 14. The expression patterns of phosphorylated
Bad at Ser 136 which normalized with b-actin in striatum and substantia nigra amongst different post-lesion time points. (G) Striatum; (H) substantia
nigra. **p,0.01; ***p,0.001, compared to control group and ipsilateral side of treated group (post- lesion day 1). ##p,0.01, compared to control
group and contralateral side of treated group (post- lesion day 1). a p,0.05; aa p,0.01; aaa p,0.001, compared to contralateral side of treated group
with the respective time point.
doi:10.1371/journal.pone.0051294.g005
Self-Repair System in Parkinson’s Disease
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Results
The activation of the cell survival mechanisms induced
after the administration of 6-hydroxydopamine
TH is the key enzyme in the conversion of the amino acid L-
tyrosine to dihydroxyphenylalanine (DOPA), which is a precursor
of dopamine. It localized with the dopamine cells and acted as an
indicator for the degeneration of dopamine cells. In the lesioned
animals, immunoreactivity for TH proteins was highly reduced
after the 6-OHDA lesion (Figure 1). A significant decrease in the
TH expression could be noticed after the post-lesion day 3.
Moreover, in the apomorphine- induced rotation test, a graduate
increase in the rotation counts (360u turn) was noted.
A number of anti-apoptotic signaling was initiated after the 6-
OHDA-induced degeneration of dopaminergic neurons. The
major signaling pathways, including PI3K/Akt cascade [27] and
ERK/MAPK cascade, were pivotal for the regulation of cell
survival [5], [27], [28], [29], [30], [31], [32], [33]. In both the
ipsilateral striatum and substantia nigra of the 6-OHDA-lesioned
rats, the phosphorylations of p44/42 MAPK kinase and Akt kinase
was increased. Robust expressions of phosphorylated p44/42
MAPK and its downstream target, phosphorylated Bad at Ser 112,
were noticed in both ipsilateral striatum and substantial nigra from
post-lesion day 3 to day 14, where their immunoreactivities peaked
at day 7 (Figure 2 and Figure 3). Phosphorylation of Akt kinase
could be observed throughout the period in all groups (Figure 4).
Figure 6. Total endogenous brain derived neurotrophic factor and glial cell-line derived neurotrophic factor were detected in the
striatum and substantia nigra of the 6-hydroxydopamine lesioned rats as well as the control group by standard ELISA assays
amongst different time points. (A) brain derived neurotrophic factor in striatum; (B) brain derived neurotrophic factor in substantia nigra; (C) glial
cell-line derived neurotrophic factor in striatum. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0051294.g006
Figure 7. Western Blotting showing that there is an up-regulation of brain-derived neurotrophic factor in both of the striatum and
substantia nigra of the 6-hydroxydopamine lesioned rats as well as the control group in different time points. Three bands are
observed. They are pro- brain-derived neurotrophic factor (32 kDa), brain-derived neurotrophic factor dimer (28 kDa) and brain-derived neurotrophic
factor monomer (14 kDa) respectively (A) Control; (B) Post-lesion day 1; (C) Post-lesion day 3; (D) Post-lesion day 5; (E) Post-lesion day 7; (F) Post-lesion
day 14. The expression trends of pro- brain-derived neurotrophic factor (G–H), brain-derived neurotrophic factor dimer (I–J) and brain-derived
neurotrophic factor monomer (K–L) of striatum and substantia nigra of the 6-hydroxydopamine lesioned rats as well as the control group during
different time points are illustrated in the graphs. **p,0.01; ***p,0.001; p,0.01; p,0.001.
doi:10.1371/journal.pone.0051294.g007
Self-Repair System in Parkinson’s Disease
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No significant changes were found amongst different groups.
Interestingly, its downstream target, phosphorylated Bad at Ser
136, illustrated a gradual and significant increase only in the
ipsilateral hemisphere of the 6-OHDA-lesioned animals (Figure 5).
Timely expressions of total brain-derived neurotrophic
factor and total glial cell line-derived neurotrophic factor
in striatum and substantia nigra of 6-hydroxydopamine
lesioned rats
The levels of total BDNF and total GDNF protein contents
were demonstrated in the ELISA assays (Figure 6). Significant
Figure 8. Western Blotting analyses showing that there is an up-regulation of glial cell-line derived neurotrophic factor both the
striatum and substantia nigra of the 6-hydroxydopamine lesioned rats as well as the control group in different time points. (A)
Control; (B) Post-lesion day 1; (C) Post-lesion day 3; (D) Post-lesion day 5; (E) Post-lesion day 7; (F) Post-lesion day 14. The expression trends of glial
cell-line derived neurotrophic factor of striatum and substantia nigra of the 6-hydroxydopamine lesioned rats as well as the control group during
different time points are illustrated in G. ***p,0.001; p,0.01.
doi:10.1371/journal.pone.0051294.g008
Self-Repair System in Parkinson’s Disease
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changes in the BDNF and GDNF levels were detected in the
ipsilateral hemisphere of the lesioned rats ([n] = 30). Moreover, we
observed that the up-regulations of the neurotrophic factors and
the cell survival mediators had similar expression patterns. It was
well-noted that BDNF and GDNF mediated their neuroprotective
effects through the activation of two main cell survival pathways,
i.e. PI3K/Akt pathway and ERK/MAPK pathway [28], [29],
[30], [31], [32], [33]. In both ipsilateral striatum and substantia
nigra, the level of BDNF significantly increased at post-lesioned
day 5 (striatum: 55.88612.87 pg/ml; substantia nigra:
56.2567.32 pg/ml) and day 7 (striatum: 42.4066.87 pg/ml;
substantia nigra: 53.97611.95 pg/ml). The GDNF expression
Figure 9. Laser scanning confocal microscopy showing (A–C) nestin, glial fibrillary acid protein, Nestin/glial fibrillary acid protein
immunoreactivity in the striatum (as indicated by arrow) and (D–F) substantia nigra (as indicated by arrow) of the 6-
hydroxydopamine-lesioned day 3 rat. Co-location of nestin with glial fibrillary acid protein can be observed. Scale bar: 25 mm. Comparisons of
the average grey value of various labeling in both of the striatum and substantia nigra. The time-dependant patterns of tyrosine hydroxylase
reactivity in striatum (G) and substantia nigra (H).
doi:10.1371/journal.pone.0051294.g009
Self-Repair System in Parkinson’s Disease
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was also displayed in the ipsilateral striatum but not in the
substantia nigra at post-lesioned day 5 (54.95610.95 pg/ml) and
day 7 (81.1867.17 pg/ml). The expression patterns of their
different molecular forms would be further explored.
Differential expressions of different molecular forms of
neurotrophic factors in nigrostriatal regions after 6-
hydroxydopamine lesion
Three bands of BDNF proteins were observed in the Western
Blotting analysis (Figure 7). These three bands were Pro-BDNF
(32 kDa), BDNF dimer (28 kDa) and BDNF monomer (14 kDa)
respectively (40). Pro-BDNF is the precursor for synthesis of
mature forms of BDNF (14 kDa). Cleavage of pro-BDNF by the
serine protease plasmin system formed BDNF monomer. Mono-
mers of BDNF were unable to bind to the TrkB receptor until the
dimerization of two BDNF monomers (28 kDa) [34]. In both the
striatum and the substantia nigra, expressions of pro-BDNF and
BDNF monomer were observed at post-lesion day 3 while the
expression of BDNF dimer was only started at post-lesion day 5
(Figure 7A–F). The levels of pro-BDNF increased significantly
from post-lesion day 3 to day 7 and declined at post-lesion day 14
(Figure 7G–H). Then the peak of BDNF dimer and BDNF
monomer expressions were found to be at post-lesion day 7
(Figure 7I–L). Interestingly, in the contralateral striatal and nigral
tissues of the 6-OHDA-lesioned rats, pro-BDNF and BDNF forms
were also up-regulated with an insignificant amount. (Figure 7G–
L). The only exception was that no significant increase in BDNF
dimer was detected in the contralateral tissues (Figure 7J).
Furthermore, the expressions of pro-BDNF and BDNF forms
were lesion-specific (Figure 7G–L).
A single 32 kDa band of GDNF homodimer was observed [35]
in the blots. GDNF protein was found to express at post-lesion day
3 and peaked at post-lesion day 7 (Figure 8). Lower levels of
GDNF proteins were also detected in the contralateral striatum
(Figure 8). This observation was consistent with the above analysis
that no GDNF protein was observed in the substantia nigra.
Reactive astrocytes are potential candidates to offer the
endogenous repair mechanisms by promoting the
expression of the neurotrophic factors
We previously reported that reactive astrocytes with nestin were
re-expressed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)- lesioned mice [29]. In the present study, nestin
immunoreactivity was also re-appeared in the astrocytes of both
the ipsilateral striatum and substantia nigra after the 6-OHDA
administration (Figure 9). Furthermore, a specific expression
pattern could be revealed in the lesioned rats ([n] = 30; Figure 9).
A low level of nestin was detected at post-lesion day 1. Its
expression then reached the peak at post-lesion day 3 and
decreased after post-lesion day 5. The expression was hardly
observed in both striatum and substantia nigra at post-lesion day
14. In the meanwhile, BDNF and GDNF were co-localized with
these nestin-positive reactive astrocytes. Quantification data
showed that 87.767.2% and 74.264.9% expressed BDNF in
the nestin-immunoreactive astrocytes of striatum and substantia
nigra respectively at post-lesion day 5, in which nestin immuno-
reactivity was still strong (Figure 10). Moreover, 83.765.8% and
62.164.6% exhibited nestin in the BDNF-immunoreactive
astrocytes of striatum and substantia nigra at post-lesion day 5
respectively. A low level of BDNF immunoreactivity was expressed
by perikarya of neurones near to BDNF immunoreactive reactive
astrocytes in the striatum but not in the substantia nigra
(Figure 10). On the other hand, quantification data showed that
46.167.3% expressed GDNF immunoreactivity in the nestin-
immunoreactive astrocytes of striatum whilst 98.261.3% of
GDNF-immunoreactive cells expressed nestin immunoreactivity
(Figure 10). These data suggested that reactive astrocytes might be
responsible for the release of the neurotrophic factors and thus
provoke the self-neuroprotective mechanisms.
Discussion
The present results have demonstrated for the first time that
astrocytes exhibit an endogenous self-repairing mechanism via
release of BDNF and/or GDNF during very early stages of rat
Parkinsonism of 6-OHDA-leisoned rats. Importantly, we have
found there is a specific sequence of events for these possible self
repair mechanisms (Figure 11). These events happen at extremely
early stages of degeneration. It is often missed in animal models
and is impossible to be discovered in patients with Parkinson’s
disease. At early post-lesion day 3, levels of TH in the ipsilateral
striatum started to lower. Nestin immunopositive reactive astro-
cytes started to appear and some of them were found to display
BNDF and/or GDNF. The number of reactive astrocytes
displayed BDNF and GDNF then reached the peak at post-lesion
day 7. Neuronal expression of BNDF was also found at this stage.
At post-lesion day 14, no more reactive astrocytes were then
observed in striatum and the transient self-repair events were
curtained. Interestingly, GDNF is not expressed by reactive
astrocytes in the substantia nigra. GDNF is strongly presented in
Figure 10. The nestin immunoreactive cells is found to be
overlapped with that of brain-derived neurotrophic factor
immunoreactive cells in both striatum and substantia nigra of
the 6-hydroxydopamine lesioend rats while that overlapped
with that of glial cell-line derived neurotrophic factor immu-
noreactive cells in the striatum. a–c show an astrocyte (arrow) that
displays brain-derived neurotrophic factor, Nestin, brain-derived neu-
rotrophic factor/Nestin immunoreactivity in striatum; d–e show an
astrocyte (arrow) that displays brain-derived neurotrophic factor,
Nestin, brain-derived neurotrophic factor/Nestin immunoreactivity in
substantia nigra; g–i show an astrocyte (arrow) that displays glial cell-
line derived neurotrophic factor, Nestin, glial cell-line derived neuro-
trophic factor/Nestin immunoreactivity in striatum. Scale bar: 50 mm.
doi:10.1371/journal.pone.0051294.g010
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the striatal medium spiny neurones that receive the dopaminergic
inputs from the substantia nigra [36]. GDNF also supports the
embryonic development and postnatal survival of dopaminergic
neurones in the substantia nigra and their axonal terminals in the
striatum [31], [32], [36]. Reactive astrocytes also appeared in the
ipsilateral substantia nigra at post-lesion day 3 and only some of
them displayed BDNF. The pattern of appearance of BDNF in
reactive astrocytes and neurones in the substantia nigra followed
that of striatum and the peak of BDNF expression was found at
post-lesion day 7. At post-lesion day 14, the self-repair events were
also curtained in the substantia nigra. In addition, based on the
above findings, ERK/MAPK pathway was most likely involved in
the endogenous neuroprotective mechanisms, particularly in early
stages of rat Parkinsonism. Phosphorylation of p44/42 MAPK
kinase as well as it downstream target, Bad (Ser 112), could be
observed significantly during the studied post-lesion period, i.e.
from post-lesion day 1 to post-lesion day 14, in response to 6-
OHDA toxin.
Among families of neurotrophic factors, BDNF and GDNF are
found to be the major factors that protect dopaminergic neurons
[28], [29], [30], [33], [37] and associated with neuronal survival,
neurite outgrowth and neuronal functions [35], [38]. Expressions
of BDNF and GDNF are found to be abundant in striatum during
embryonic and early postnatal development [29]. However, in the
normal adult rats, BDNF exists at a low level while GDNF is
undetectable [5]. The neuroprotective effect of BDNF and GDNF
probably is mediated by inducing phosphorylations of several
signaling proteins which inhibits the apoptotic signaling from the
Figure 11. (A) Unilateral administration of 6-hydroxydopamine in striatum induces a significant degeneration of ipsilateral substantia nigra through
the nigrostriatal pathway. (B) The expression of nestin-immunoreactive reactive astrocytes is found to peak at post-lesion day 3. Low levels of
expression of brain derived neurotrophic factor in reactive astrocytes are found in the ipsilateral striatum as well as the ipsilateral substantia nigra.
Expression of glial cell-line derived neurotrophic factor is found in the ipsilateral striatum only. (C) The expression of nestin in reactive astrocytes
drops to a low level in both ipsilateral striatum and ipsilateral substantia nigra at post-lesion day 7. However, the expressions of the brain-derived
neurotrophic factor and glial cell-line neurotrophic factor in the reactive astrocytes are found to be peaked at the same period. The expression of
brain-derived neurotrophic factor can be found in the neurones of the ipislateral striatum and substantia nigra, as well as the contralateral striatum,
but in a small amount. (D) No expressions of nestin, brain derived neurotrophic factor and glial cell-line derived neurotrophic factor
immunoreactivities are found in the striatum and substantia nigra at post-lesion day 14.
doi:10.1371/journal.pone.0051294.g011
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brain insults and toxins [28]. BDNF binds to Trk B receptors and
initiates a number of anti-apoptotic signaling pathways including
phorphtidylinositol 3-kinase (PI3K)/Akt pathway [27], [39].
Activation of these pathways promotes Bcl-xL/Bcl-2-associated
death promoter (BAD) at Ser 136 and at Ser 112. These
phosphorylations lead to inhibition of the apoptotic pathways
and thus enhance cell survival [28], [40], [41], [42], [43], [44],
[45], [46], [47], [48]. On the other hand, GDNF binds to RET, a
tyrosine kinase receptor and then induces the autophosphorylation
of RET [27], [28], [39], [40], [41], [42], [43], [44], [45], [46],
[47], [49]. This phosphorylation also activates the PI3K/Akt
pathway [28], [49]. Release of BDNF and GDNF from reactive
astrocytes are therefore able to promote survival of the degener-
ating dopaminergic neurones after exposure to 6-OHDA.
Many intensive researches were done both preclinically and
clinically on the efficacy of the neurotrophic factors as the
treatment of Parkinson’s disease. Previous studies in animals and
in clinical trials have indicated that delivery of GDNF and BDNF
have provided certain degrees of efficacy in treatments of
Parkinsonian patients [31], [32], [36]. However, clinical trials of
GDNF infusions on 34 patients failed recently due to unexpected
immune responses in approximately half of the patients and some
resulted in mortality. It is still not clear whether these unfortunate
events are deal to the infusion of GDNF or some other causes
including heart attack [50], [51]. Despite the fact that current
clinical trials are underway employing infusion of BDNF or gene
transfection of neurturin, there is often a risk in administration of
exogenous growth factors into the nervous systems [31], [32], [36].
Our findings are important because the results indicate that there
is an endogenous process that can release endogenous BNDF and
GDNF from reactive astrocytes upon onset of Parkinson’s disease.
These demonstrate directly that the nervous system has the ability
to exercise self repair at least at the very early beginning of the
degenerative process. If the repair mechanisms can be maintained
for longer time period, it can have significant clinical implications.
The rationale for putting exogenous BDNF and GDNF may need
to be re-visited.
In addition to release of BDNF and GDNF, previous studies
have shown reactive astrocytes facilitated neuroprotective and
neurotrophic effect on dopaminergic neurons [52], [53], [54],
[55]. However, a key issue here is that it is unknown how an
astrocyte turns reactive and the triggering mechanism of the nestin
re-expression. It is suggested to trigger by oxidative stress
mechanisms [56], [57], [58] and the release of triggering factors
such as the excitatory amino acids derived from the damaged
dopaminergic neurons [29]. Others have hypothesized that
astrocytic network is linked by gap junctions and direct
information about neuronal damage or reduced neuronal activity
from the site of damage can be passed from one area to the others
[59], [60]. Degeneration of neurones will also interrupt the glial
communication and lead to a decrease the gap junctions amongst
the astrocytes and causes the astrocytes turn reactive [58], [60].
In reactive astrocytes, astrocytic Ca2+ oscillations have been well
documented [61], [62], [63]. When astrocytes turn reactive, Ca2+
are released from internal stores of astrocytes with additional
influx of extracellular Ca2+ through voltage-gated channel, and
thus result in a transient Ca2+ oscillations [61], [64]. Ca2+
regulated the transcriptions of BDNF and GDNF through the
cAMP response element binding (CREB)-dependent mechanism
[64], [65] and mitogen-activated protein (MAP) kinase-dependent
and -independent pathways [66]. Increases in intracellular Ca2+ is
known to enhance the synthesis of pro-BNDF and pro-GDNF,
and therefore the increased Ca2+ levels in reactive astrocytes then
trigger the release of BDNF as well as GDNF. In addition, Ca2+ is
required for complex formation between RET and GDNF to form
signal transducing complex [67] so as to activate the anti-apoptotic
pathways.
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